Functioning Disturbance in Chronic Back Pain: Altered Muscle Metabolism
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Aage Indahl, PhD, MD
- Phone Number: (+47)33134045
- Email: aage.indahl@siv.no
Study Contact Backup
- Name: Vegard Pihl Moen, PT, MSc
- Phone Number: (+47)33134097
- Email: vegard.pihl.moen@siv.no
Study Locations
-
-
-
Stavern, Norway, 3290
- Recruiting
- Kysthospitalet, Vestfold Hospital Trust
-
Contact:
- Aage Indahl, MD, PhD
- Phone Number: +4791765888
- Email: aage.indahl@siv.no
-
Contact:
- Vegar Phil Moen, MS
- Phone Number: +4792438242
- Email: Vegar.Phil.Moen@siv.no
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
The NSCBP group:
- At least 6 patients will be included in this study.
- All patients referred to Vestfold Hospital Trust, Kysthospitalet, diagnosed with chronic NSCBP >3 months duration will be invited to participate in the study. The invitation will be in a written form.
Exclusion Criteria:
- anamnesis of medical or drug abuse,
- surgery on the musculoskeletal system of the trunk,
- known congenital malformation of the spine or scoliosis,
- body mass index > 27 kg/m2,
- systemic-neurological-degenerative disease,
- history of stroke,
- psychiatric disorder,
- pregnancy and abnormal blood pressure. The subjects will be asked not to use any medications except for paracetamol preparations one week before examination and instructed not to perform any back-straining exercise for 48 h prior to the study, except for ordinary daily working and/or leisure activities.
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Cross-Sectional
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 182006/V50
- 08/5253 Personvernombudet RRHF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.